Google AI for Health Program Selects Five African Startups

By HEOR Staff Writer

October 26, 2023

AI for Health program

A New Era for African Health Startups

The 2023 cohort of the Google for Startups Growth Academy: AI for Health program has been announced. The aforementioned selection comprises a total of 30 startup companies. All originating from the regions of Europe, the Middle East, and Africa. Out of the selection, five African firms have been designated, namely mDoc and PharmaRun from Nigeria.

The selection of these firms is based on their utilization of artificial intelligence (AI) in a pioneering manner to address health-related obstacles. They have the potential to enhance healthcare by implementing artificial intelligence (AI)-based solutions. This encompasses a wide range of areas, spanning from the early diagnosis of diseases to the promotion of universal access to information.

 

The Conceptual Framework Underlying the Program

Yuval Passov, the Head of Google for entrepreneurs, articulated his perspective on the potential of African health entrepreneurs utilizing artificial intelligence (AI). The author found Africa’s pioneering attitude in the field of AI for Health to be highly motivating. The chosen startups serve as evidence of the continent’s capacity to create worldwide health solutions. Google’s objective is to align itself with these entities, providing assistance and collaboration as they endeavor to expand and distribute their innovative solutions.

The Google for businesses Growth Academy: AI for Health program aligns with Google’s goal to help businesses grow faster. This program aims to support selected African and international companies. It strives to encourage innovation and healthcare advancements. Ultimately, it seeks to create a lasting positive impact on global welfare.

Reference url

Recent Posts

Levacetylleucine A-T treatment
Transformative Impact of Levacetylleucine A-T Treatment in Rare Neurodegenerative Disease

By HEOR Staff Writer

June 8, 2026

Levacetylleucine A-T treatment has delivered compelling Phase III results, producing statistically significant and clinically meaningful improvements in ataxia severity and daily function for both pediatric and adult patients with ataxia-telangiectasia (A-T). The
Insulin Cost Policy Impact
Insulin Cost Policy Impact on Medicare Beneficiaries

By HEOR Staff Writer

June 8, 2026

The Insulin Cost Policy Impact became clear in 2023 after the Inflation Reduction Act limited out-of-pocket insulin expenses to $35 per 30-day supply for Medicare Part D beneficiaries. According to a JAMA Network study, the c...
Parkinson's Cognitive Measurement
Parkinson’s Cognitive Measurement and the Impact of Precision on Forecasting

By João L. Carapinha

June 8, 2026

Parkinson's Cognitive Measurement has emerged as the decisive constraint on our ability to forecast cognitive decline in Parkinson disease. A major new analysis shows that even the most advanced machine learning models deliver only chance-level accuracy when predicting individual cognitive trajec...